Ryan Allway January 4th, 2022 Psychedelics The clinical trial at the University of Toronto will study low doses of psilocybin in healthy subjectswith persistent depressive disorder VANCOUVER, BC, Jan. 4, 2022 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, today announced... Read more